InfertilityNCT05716139
Natural Cycle vs Programmed Cycle Frozen Embryo Transfer
A study testing Natural Cycle and Artificial Cycle in people with Infertility and Frozen Embryo Transfer, run by Indira IVF Hospital Pvt Ltd at 1 site in India.
Trial summary
The goal of this[ type of study: randomized controlled trial]is to compare Preeclampsia following Natural vs. Artificial Cycle in patients undergoing frozen embryo transfer. The main question[s] it aims to answer is Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as… Read more about this study
- Who is it for?
- Ages 21 to 45 years, women only
- Conditions the study is for
- Infertility, Frozen Embryo Transfer, Preeclampsia and Eclampsia
- What is being tested?
- Natural Cycle and Artificial Cycle
- Type of treatment
- Pill or oral medicine, Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 172 participants
- Where
- 1 siteIndia
- Study dates
- 15 Jul 2023to 26 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Endometrial preparation with Hormone replacement therapy/ Natural cycle.
- Age 21-45 years following an autologous IVF cycle (with or without preimplantation genetic testing for aneuploidy)
- BMI > 18 and < 30 kg/m2
- Endometrial thickness ≥ 7 mm after estrogen therapy or on the day of ovulation
- Blastocyst embryo transfer
Who cannot join
- Uterine diseases (e.g. submucosal fibroids, polyps, previously diagnosed Müllerian abnormalities)
- Hydrosalpinx untreated.
- Recurrent pregnancy loss (≥ 3 previous miscarriages)
- Recurrent implantation failure (≥ 3 previously failed embryo transfers of good-quality blastocysts)
- Allergy to study medication
- Pregnancy or lactation at recruitment
- Contraindications for hormonal treatment
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Preeclampsia Following Natural vs. Artificial Cycle Frozen Embryo Transfer
The goal of this[ type of study: randomized controlled trial]is to compare Preeclampsia following Natural vs. Artificial Cycle in patients undergoing frozen embryo transfer.
The main question[s] it aims to answer is
Read more
- Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as compared to AC-FET ?
The main objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. Participants recruited will be divided into two ARM(1513 per arm). ARM 1 will undergo the Natural Cycle procedure of Embryo transfer, and ARM 2 will undergo the Artificial Cycle procedure of Embryo transfer. The primary outcome will be the proportion of preeclampsia. The duration of the study is around 2 year.
Read the detailed description
The Research question(PICO) addressed is Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as compared to AC-FET . The hypothesis taken is NC-FET will decrease the incidence of preeclampsia compared to AC-FET. The sample size is taken as 3026 (1513 per arm). The Primary Objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. The study outcome of the proportion of preeclampsia after 20 weeks of gestation or 6 weeks post-delivery. There are two arms-Arm 1 Active Comparator: Natural Cycle and Arm 2 control: Artificial Cycle FET. The Randomization is done through Random Allocation as per computer generated sequence. The Blinding/masking is done Open labeled. The Study Duration is from Feb 2023 to Jan 2025. Participation Duration is 10 months.
- Being tested
- Natural Cycle, Artificial Cycle
- Keywords
- Reproduction, In vitro fertilization, Natural Frozen Embryo Transfer, Artificial Frozen Embryo Transfer, Preeclampsia
- Medical subject headings
- Infertility, Pre-Eclampsia, Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Natural CycleProcedure or surgery
The participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH < 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation.
Artificial CycleProcedure or surgery
Estrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping.
| Study group | Role | What they receive |
|---|---|---|
| Natural Cycle | Active comparator | In this,hCG trigger and Luteal Phase Support is monitored for the natural frozen embryo cycle procedure of IVF. Receives: Procedure: Natural Cycle |
| Artificial Cycle | Other | In this, endometrial preparation and Luteal Phase Support is monitored for the artificial frozen embryo cycle procedure of IVF. Receives: Procedure: Artificial Cycle |
What is being measured
The primary outcome is the main question the study is designed to answer.
proportion of preeclampsia
The primary efficacy endpoint is the proportion of preeclampsia in women assigned to a natural cycle protocol compared to the proportion of preeclampsia in women assigned to an artificial cycle protocol.
Measured: after the 20th week of gestation up to six weeks postpartum
Secondary outcomes (17)
Biochemical Pregnancy Rate
Pregnancies diagnosed only by β-human chorionic gonadotropin detection without a gestational sac visualized by vaginal ultrasound at the 6th gestational week.
Measured: 6 weeks after Embryo Transfer
Implantation Rate
The number of gestational sacs observed by transvaginal ultrasound at the 6th gestational week per the number of embryos transferred.
Measured: 4 weeks +2 weeks after ET
Clinical Pregnancy Rate
Detection of a foetal heartbeat on transvaginal ultrasound at the 6th gestational week per embryo transfer cycle.
Measured: 4 weeks +2 weeks after ET
Ongoing Pregnancy Rate
Presence of gestational sacs with a heartbeat at the 12th gestational week per embryo transfer cycle.
Measured: 12 weeks after embryo Transfer
Live Birth Rate
The number of deliveries that resulted in at least one live birth per 100 Embryo transferred cycle.
Measured: 28 weeks(+12 weeks) after embryo transfer
Miscarriage Rate
Number of spontaneous pregnancy losses in which a gestational sac/s was previously observed (before 20th gestational weeks) per 100 clinical pregnancy.
Measured: Within 20 weeks of gestation
Preterm birth
Preterm is defined as babies born alive before 37 weeks of pregnancy are completed
Measured: < 37 weeks
Extreme preterm birth
Extreme Preterm is defined as babies born alive before 28 weeks of pregnancy
Measured: 20-28 weeks
Fetal growth restriction
Fetal growth restriction (FGR) is most often defined as an estimated fetal weight less than the 10th percentile for gestational age by prenatal ultrasound evaluation
Measured: 20-40 weeks of gestation
Fetal birthweight
Is defined as the weight of baby just after birth
Measured: within 30 minutes of birth
Premature detachment of normally inserted placenta
It is defined as a premature separation of the placenta before delivery.
Measured: 12 weeks of GA till labor
Maternal hypertension
It is defined as blood pressure more than 140/90 mm Hg detected first time after 20 weeks of gestation till 6 weeks of postpartum without proteinuria
Measured: After 20 weeks of GA till 6 weeks postpartum
Eclampsia
Eclampsia is defined as the new onset of generalized tonic-clonic seizures in a woman with preeclampsia.
Measured: After 20 weeks of GA till 6 weeks postpartum
HELLP Syndrome
It is defined as hemodialysis, elevated liver enzymes, and low platelet count
Measured: After 20 weeks of GA till 6 weeks postpartum
Maternal mortality
Maternal death is defined as pregnancy or its management (excluding accidental or incidental causes) during pregnancy and childbirth or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy
Measured: from start of pregnancy to 42 weeks of pregnancy
Fetal death
Fetal death refers to the spontaneous intrauterine death of a fetus after 20 weeks of GA before delivery
Measured: 20 weeks of GA before delivery
Frequency of adverse events
An adverse event (AE) is any untoward medical occurrence in a patient.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Feb 2023
- Study start15 Jul 2023
- Primary completion26 Mar 2024
- Study completion26 Mar 2024
Why it stopped: As per institutional protocol unable to recruit adequate amount of participants
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for InfertilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Open labelled parallel group randomized Controlled Trial
- Masking
- None (open label)
- Enrolment
- 172 participants (actual)
Sponsor and investigators
- Lead sponsor
- Indira IVF Hospital Pvt Ltd
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05716139
- Sponsor's protocol ID
- IIHPL-UDR/RCT/013_2022
- Status last verified
- Jul 2023
- First submitted
- 21 Jan 2023
- Last updated
- 3 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: IPD will be shared with other researchers after publication of primary results.
Publications
Ginstrom Ernstad E, Wennerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles. Am J Obstet Gynecol. 2019 Aug;221(2):126.e1-126.e18. doi: 10.1016/j.ajog.2019.03.010. Epub 2019 Mar 22.
PubMed 30910545American College of Obstetricians and Gynecologists' Committee on Obstetric Practice; Committee on Genetics; U.S. Food and Drug Administration. Committee Opinion No 671: Perinatal Risks Associated With Assisted Reproductive Technology. Obstet Gynecol. 2016 Sep;128(3):e61-8. doi: 10.1097/AOG.0000000000001643.
PubMed 27548556Baksh S, Casper A, Christianson MS, Devine K, Doody KJ, Ehrhardt S, Hansen KR, Lathi RB, Timbo F, Usadi R, Vitek W, Shade DM, Segars J, Baker VL; NatPro Study Group. Natural vs. programmed cycles for frozen embryo transfer: study protocol for an investigator-initiated, randomized, controlled, multicenter clinical trial. Trials. 2021 Sep 27;22(1):660. doi: 10.1186/s13063-021-05637-3.
PubMed 34579768Busnelli A, Schirripa I, Fedele F, Bulfoni A, Levi-Setti PE. Obstetric and perinatal outcomes following programmed compared to natural frozen-thawed embryo transfer cycles: a systematic review and meta-analysis. Hum Reprod. 2022 Jun 30;37(7):1619-1641. doi: 10.1093/humrep/deac073.
PubMed 35553678Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011 Oct;26(10):2593-7. doi: 10.1093/humrep/der251. Epub 2011 Aug 9.
PubMed 21828116Kawwass JF, Badell ML. Maternal and Fetal Risk Associated With Assisted Reproductive Technology. Obstet Gynecol. 2018 Sep;132(3):763-772. doi: 10.1097/AOG.0000000000002786.
PubMed 30095760Lee JC, Badell ML, Kawwass JF. The impact of endometrial preparation for frozen embryo transfer on maternal and neonatal outcomes: a review. Reprod Biol Endocrinol. 2022 Feb 28;20(1):40. doi: 10.1186/s12958-021-00869-z.
PubMed 35227270Luke B. Pregnancy and birth outcomes in couples with infertility with and without assisted reproductive technology: with an emphasis on US population-based studies. Am J Obstet Gynecol. 2017 Sep;217(3):270-281. doi: 10.1016/j.ajog.2017.03.012. Epub 2017 Mar 18.
PubMed 28322775Malik A, Jee B, Gupta SK. Preeclampsia: Disease biology and burden, its management strategies with reference to India. Pregnancy Hypertens. 2019 Jan;15:23-31. doi: 10.1016/j.preghy.2018.10.011. Epub 2018 Nov 2.
PubMed 30825923Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, Vanderpoel S, Racowsky C. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017 Mar 1;23(2):139-155. doi: 10.1093/humupd/dmw038.
PubMed 27827818von Versen-Hoynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Stan Williams R, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, Zhang W, Winn VD, Segal MS, Conrad KP, Baker VL. Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum. Hypertension. 2019 Mar;73(3):640-649. doi: 10.1161/HYPERTENSIONAHA.118.12043.
PubMed 30636552Chen JZ, Sheehan PM, Brennecke SP, Keogh RJ. Vessel remodelling, pregnancy hormones and extravillous trophoblast function. Mol Cell Endocrinol. 2012 Feb 26;349(2):138-44. doi: 10.1016/j.mce.2011.10.014. Epub 2011 Oct 25.
PubMed 22051447Shi Y, Sun Y, Hao C, Zhang H, Wei D, Zhang Y, Zhu Y, Deng X, Qi X, Li H, Ma X, Ren H, Wang Y, Zhang D, Wang B, Liu F, Wu Q, Wang Z, Bai H, Li Y, Zhou Y, Sun M, Liu H, Li J, Zhang L, Chen X, Zhang S, Sun X, Legro RS, Chen ZJ. Transfer of Fresh versus Frozen Embryos in Ovulatory Women. N Engl J Med. 2018 Jan 11;378(2):126-136. doi: 10.1056/NEJMoa1705334.
PubMed 29320646
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Preeclampsia Following Natural vs. Artificial Cycle Frozen Embryo Transfer
- ClinicalTrials.gov ID
- NCT05716139
- Acronym / sponsor ID
- IIHPL-UDR/RCT/013_2022
- Keywords
- Reproduction, In vitro fertilization, Natural Frozen Embryo Transfer, Artificial Frozen Embryo Transfer, Preeclampsia
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: As per institutional protocol unable to recruit adequate amount of participants
- Enrolment
- 172 participants (actual)
- Lead sponsor
- Indira IVF Hospital Pvt LtdUniversity, hospital or other
- Study start
- 15 Jul 2023 (actual)
- Primary completion
- 26 Mar 2024 (actual)
- Study completion
- 26 Mar 2024 (actual)
- First posted
- 8 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this[ type of study: randomized controlled trial]is to compare Preeclampsia following Natural vs. Artificial Cycle in patients undergoing frozen embryo transfer.
The main question[s] it aims to answer is
- Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as compared to AC-FET ?
The main objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. Participants recruited will be divided into two ARM(1513 per arm). ARM 1 will undergo the Natural Cycle procedure of Embryo transfer, and ARM 2 will undergo the Artificial Cycle procedure of Embryo transfer. The primary outcome will be the proportion of preeclampsia. The duration of the study is around 2 year.
Detailed description
The Research question(PICO) addressed is Does NC-FET decreases the incidence of preeclampsia in patients undergoing frozen embryo transfer as compared to AC-FET . The hypothesis taken is NC-FET will decrease the incidence of preeclampsia compared to AC-FET. The sample size is taken as 3026 (1513 per arm). The Primary Objective is to compare the proportion of preeclampsia in women with a viable pregnancy with natural cycle protocol to artificial cycle protocol when practicing frozen embryo transfer. The study outcome of the proportion of preeclampsia after 20 weeks of gestation or 6 weeks post-delivery. There are two arms-Arm 1 Active Comparator: Natural Cycle and Arm 2 control: Artificial Cycle FET. The Randomization is done through Random Allocation as per computer generated sequence. The Blinding/masking is done Open labeled. The Study Duration is from Feb 2023 to Jan 2025. Participation Duration is 10 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Open labelled parallel group randomized Controlled Trial
| Arm | Type | Receives |
|---|---|---|
| Natural Cycle | Active comparator | Procedure: Natural CycleIn this,hCG trigger and Luteal Phase Support is monitored for the natural frozen embryo cycle procedure of IVF. |
| Artificial Cycle | Other | Procedure: Artificial CycleIn this, endometrial preparation and Luteal Phase Support is monitored for the artificial frozen embryo cycle procedure of IVF. |
Who may qualify
- Ages
- 21 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Endometrial preparation with Hormone replacement therapy/ Natural cycle.
- Age 21-45 years following an autologous IVF cycle (with or without preimplantation genetic testing for aneuploidy)
- BMI > 18 and < 30 kg/m2
- Endometrial thickness ≥ 7 mm after estrogen therapy or on the day of ovulation
- Blastocyst embryo transfer
Key exclusion criteria (7 listed)
- Uterine diseases (e.g. submucosal fibroids, polyps, previously diagnosed Müllerian abnormalities)
- Hydrosalpinx untreated.
- Recurrent pregnancy loss (≥ 3 previous miscarriages)
- Recurrent implantation failure (≥ 3 previously failed embryo transfers of good-quality blastocysts)
- Allergy to study medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Natural CycleThe participant will be administered a S/C injection of 250mcg r-hCG to assist ovulation and timing of the embryo transfer, when the dominant follicle reaches ≥ 18mm and serum LH < 20 IU/L, the administration of r-hCG will be in the evening, and the embryo transfer will be scheduled seven days later (window of ± two days). The participant will begin transvaginal progesterone gel (8 %) twice daily starting 36 hrs after the trigger until ten weeks of gestation. | Procedure or surgery | Natural Cycle |
| Artificial CycleEstrogen priming with oral estradiol valerate 6mg/day (2mg every 8 hours) starting from cycle D1-D5 after a first TVU. TVU will be performed 10-15 days after beginning estradiol until ET ≥ 7mm, maximum until 21 days. Patients will begin progesterone injection 100mg/day until blastocyst transfer. Frozen embryo transfer will be performed on day 6 +/- 2 days of progesterone administration. After embryo transfer, a supplementation with transvaginal progesterone gel (8 %) twice daily starting from the day of embryo transfer until ten weeks of gestation. Patients will continue Estradiol 2 mg thrice daily until 6 weeks of gestation; then dose tapering will be done to 2 mg twice daily until 9 wks of gestation. From 9th wk the estrogen dose will be tapered further to 2 mg once daily for 10 days before stopping. | Procedure or surgery | Artificial Cycle |
Primary outcome
proportion of preeclampsia
Time frame: after the 20th week of gestation up to six weeks postpartum
The primary efficacy endpoint is the proportion of preeclampsia in women assigned to a natural cycle protocol compared to the proportion of preeclampsia in women assigned to an artificial cycle protocol.
17 secondary outcomes
Biochemical Pregnancy Rate
Time frame: 6 weeks after Embryo Transfer
Implantation Rate
Time frame: 4 weeks +2 weeks after ET
Clinical Pregnancy Rate
Time frame: 4 weeks +2 weeks after ET
Ongoing Pregnancy Rate
Time frame: 12 weeks after embryo Transfer
Live Birth Rate
Time frame: 28 weeks(+12 weeks) after embryo transfer
Miscarriage Rate
Time frame: Within 20 weeks of gestation
Preterm birth
Time frame: < 37 weeks
Extreme preterm birth
Time frame: 20-28 weeks
Fetal growth restriction
Time frame: 20-40 weeks of gestation
Fetal birthweight
Time frame: within 30 minutes of birth
Premature detachment of normally inserted placenta
Time frame: 12 weeks of GA till labor
Maternal hypertension
Time frame: After 20 weeks of GA till 6 weeks postpartum
Eclampsia
Time frame: After 20 weeks of GA till 6 weeks postpartum
HELLP Syndrome
Time frame: After 20 weeks of GA till 6 weeks postpartum
Maternal mortality
Time frame: from start of pregnancy to 42 weeks of pregnancy
Fetal death
Time frame: 20 weeks of GA before delivery
Frequency of adverse events
Time frame: through study completion, an average of 1 year
Results and safety
The study was stopped early (reason given: As per institutional protocol unable to recruit adequate amount of participants). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2025.
- Background: PubMed 30910545Ginstrom Ernstad E, Wennerholm UB, Khatibi A, Petzold M, Bergh C. Neonatal and maternal outcome after frozen embryo transfer: Increased risks in programmed cycles. Am J Obstet Gynecol. 2019 Aug;221(2):126.e1-126.e18. doi: 10.1016/j.ajog.2019.03.010. Epub 2019 Mar 22.
- Results publication: PubMed 27548556American College of Obstetricians and Gynecologists' Committee on Obstetric Practice; Committee on Genetics; U.S. Food and Drug Administration. Committee Opinion No 671: Perinatal Risks Associated With Assisted Reproductive Technology. Obstet Gynecol. 2016 Sep;128(3):e61-8. doi: 10.1097/AOG.0000000000001643.
- Results publication: PubMed 34579768Baksh S, Casper A, Christianson MS, Devine K, Doody KJ, Ehrhardt S, Hansen KR, Lathi RB, Timbo F, Usadi R, Vitek W, Shade DM, Segars J, Baker VL; NatPro Study Group. Natural vs. programmed cycles for frozen embryo transfer: study protocol for an investigator-initiated, randomized, controlled, multicenter clinical trial. Trials. 2021 Sep 27;22(1):660. doi: 10.1186/s13063-021-05637-3.
- Results publication: PubMed 35553678Busnelli A, Schirripa I, Fedele F, Bulfoni A, Levi-Setti PE. Obstetric and perinatal outcomes following programmed compared to natural frozen-thawed embryo transfer cycles: a systematic review and meta-analysis. Hum Reprod. 2022 Jun 30;37(7):1619-1641. doi: 10.1093/humrep/deac073.
- Results publication: PubMed 21828116Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011 Oct;26(10):2593-7. doi: 10.1093/humrep/der251. Epub 2011 Aug 9.
- Results publication: PubMed 30095760Kawwass JF, Badell ML. Maternal and Fetal Risk Associated With Assisted Reproductive Technology. Obstet Gynecol. 2018 Sep;132(3):763-772. doi: 10.1097/AOG.0000000000002786.
- Results publication: PubMed 35227270Lee JC, Badell ML, Kawwass JF. The impact of endometrial preparation for frozen embryo transfer on maternal and neonatal outcomes: a review. Reprod Biol Endocrinol. 2022 Feb 28;20(1):40. doi: 10.1186/s12958-021-00869-z.
- Results publication: PubMed 28322775Luke B. Pregnancy and birth outcomes in couples with infertility with and without assisted reproductive technology: with an emphasis on US population-based studies. Am J Obstet Gynecol. 2017 Sep;217(3):270-281. doi: 10.1016/j.ajog.2017.03.012. Epub 2017 Mar 18.
- Results publication: PubMed 30825923Malik A, Jee B, Gupta SK. Preeclampsia: Disease biology and burden, its management strategies with reference to India. Pregnancy Hypertens. 2019 Jan;15:23-31. doi: 10.1016/j.preghy.2018.10.011. Epub 2018 Nov 2.
- Results publication: PubMed 27827818Rienzi L, Gracia C, Maggiulli R, LaBarbera AR, Kaser DJ, Ubaldi FM, Vanderpoel S, Racowsky C. Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update. 2017 Mar 1;23(2):139-155. doi: 10.1093/humupd/dmw038.
- Results publication: PubMed 30636552von Versen-Hoynck F, Schaub AM, Chi YY, Chiu KH, Liu J, Lingis M, Stan Williams R, Rhoton-Vlasak A, Nichols WW, Fleischmann RR, Zhang W, Winn VD, Segal MS, Conrad KP, Baker VL. Increased Preeclampsia Risk and Reduced Aortic Compliance With In Vitro Fertilization Cycles in the Absence of a Corpus Luteum. Hypertension. 2019 Mar;73(3):640-649. doi: 10.1161/HYPERTENSIONAHA.118.12043.
- Results publication: PubMed 22051447Chen JZ, Sheehan PM, Brennecke SP, Keogh RJ. Vessel remodelling, pregnancy hormones and extravillous trophoblast function. Mol Cell Endocrinol. 2012 Feb 26;349(2):138-44. doi: 10.1016/j.mce.2011.10.014. Epub 2011 Oct 25.
- Individual participant dataSharing planned: Yes. IPD will be shared with other researchers after publication of primary results.
Related trials for Infertility
RecruitingPhase 3
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Infertility
Active, not recruitingObservational study
Fresh Versus Vitrified-Warmed Donor Oocytes: Embryological and Clinical Outcomes
Infertility, Donor Oocyte Assisted Reproduction
RecruitingObservational study
Safety and Efficacy of Corifollitropin Alfa N02 Injection in Elderly Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Active, not recruiting
Automation of the In Vitro Fertilization Laboratory
Infertility, ART
Not yet recruiting
Implementing IVM for Fertility Treatment in Clinical Practice
Infertility
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Natural Cycle and Artificial Cycle in people with Infertility and Frozen Embryo Transfer, run by Indira IVF Hospital Pvt Ltd at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 3 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: As per institutional protocol unable to recruit adequate amount of participants). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
proportion of preeclampsia (time frame: after the 20th week of gestation up to six weeks postpartum). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05716139, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2025.